Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification

Condition(s) studied

Investigational drug(s) / intervention(s)

Observational: The goal is to determine whether the new 2021 WHO classification, based on cIMPACT-NOW recommendations, results in more homogeneous patient groups than the old 2016 classification. Furthermore, it will help derive provisional guidelines on how patients with these newly defined tumour entities are best treated. These recommendations will be based on the experience of EORTC investigators with chosen treatments and their experience as reported in this data collection report.

Study summary

Every new classification depends on its prognostic power and on the type of treatment given. With the rapid evolution of diagnostic methods and the advance in new treatments, there is much less reliable information available on how patients with newly defined brain tumour entities should be treated and what to expect from the current treatments.

The goal is to determine whether the new 2021 WHO classification, based on cIMPACT-NOW recommendations, results in more homogeneous patient groups than the old 2016 classification. Furthermore, it will help derive provisional guidelines on how patients with these newly defined tumour entities are best treated. These recommendations will be based on the experience of EORTC investigators with chosen treatments and their experience as reported in this data collection report.

Eligibility

Primary outcome measure(s)

• Best overall and objective response — Followed up for 10 years
  Recorded from the date start of an anti-tumor therapy until disease progression or start of a new anti-tumor therapy.
• Progression free survival — Followed up for 10 years
  From the date of start of the anti-tumor therapy until the date of first objective progression as determined by the local investigator or the date of patient's death whichever occurs first. Patients will be followed up for 5 years after enrolment.
• Overall Survival — Followed up for 10 years
  Calculated from the date of first pathological diagnosis of the brain tumour; Until the date of death from any cause
• Patient and Disease Characteristics — At enrolment and updated every 6 months during follow-up, up to 10 years
  Eligibility, demographics, comorbidities, molecular data

Trial sites (42)

+ 2 more sites — see the full list on the official registry below.

More European Organisation for Research and Treatment of Cancer - EORTC trials in Germany

Other trials for the same condition